GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TWi Biotechnology Inc (ROCO:6610) » Definitions » EV-to-FCF

TWi Biotechnology (ROCO:6610) EV-to-FCF : -5.99 (As of Apr. 07, 2025)


View and export this data going back to 2016. Start your Free Trial

What is TWi Biotechnology EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, TWi Biotechnology's Enterprise Value is NT$932.54 Mil. TWi Biotechnology's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was NT$-155.72 Mil. Therefore, TWi Biotechnology's EV-to-FCF for today is -5.99.

The historical rank and industry rank for TWi Biotechnology's EV-to-FCF or its related term are showing as below:

ROCO:6610' s EV-to-FCF Range Over the Past 10 Years
Min: -31.37   Med: -11.07   Max: -0.21
Current: -5.99

During the past 12 years, the highest EV-to-FCF of TWi Biotechnology was -0.21. The lowest was -31.37. And the median was -11.07.

ROCO:6610's EV-to-FCF is ranked worse than
100% of 460 companies
in the Biotechnology industry
Industry Median: 2.335 vs ROCO:6610: -5.99

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-04-07), TWi Biotechnology's stock price is NT$11.85. TWi Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was NT$-1.787. Therefore, TWi Biotechnology's PE Ratio (TTM) for today is At Loss.


TWi Biotechnology EV-to-FCF Historical Data

The historical data trend for TWi Biotechnology's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TWi Biotechnology EV-to-FCF Chart

TWi Biotechnology Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.71 -13.20 -14.10 -6.77 -6.79

TWi Biotechnology Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.10 - -6.77 - -6.79

Competitive Comparison of TWi Biotechnology's EV-to-FCF

For the Biotechnology subindustry, TWi Biotechnology's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TWi Biotechnology's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TWi Biotechnology's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where TWi Biotechnology's EV-to-FCF falls into.


;
;

TWi Biotechnology EV-to-FCF Calculation

TWi Biotechnology's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=932.536/-155.721
=-5.99

TWi Biotechnology's current Enterprise Value is NT$932.54 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. TWi Biotechnology's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was NT$-155.72 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TWi Biotechnology  (ROCO:6610) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

TWi Biotechnology's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=11.85/-1.787
=At Loss

TWi Biotechnology's share price for today is NT$11.85.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. TWi Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was NT$-1.787.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


TWi Biotechnology EV-to-FCF Related Terms

Thank you for viewing the detailed overview of TWi Biotechnology's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


TWi Biotechnology Business Description

Traded in Other Exchanges
N/A
Address
Lane 221, Kang Chien Road, 8th Floor, Number 41, Neihu District, Taipei, TWN, 11494
TWi Biotechnology Inc is a clinical-stage biopharmaceutical company based in Taiwan. It is engaged in the development of new drugs for unmet medical needs, particularly in the diseases associated with innate immunity. The pipeline products of the company comprise AC-201, AC-203, and AC-701.

TWi Biotechnology Headlines

No Headlines